ACE and chronic kidney disease: Namely, the documented inability to take an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) was an exclusion criterion for the DAPA-CKD trial, while this was not the case for the EMPA-KIDNEY trial (Heerspink et al., 2020; The EMPA-KIDNEY Collaborative Group Herrington et al., 2023).